Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Zaleplon
Drug ID BADD_D02379
Description Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.
Indications and Usage For the treatment of short-term treatment of insomnia in adults.
Marketing Status Prescription; Discontinued
ATC Code N05CF03
DrugBank ID DB00962
KEGG ID D00530
MeSH ID C085665
PubChem ID 5719
TTD Drug ID D09DWL
NDC Product Code 50090-1564; 43063-783; 43063-505; 0054-0084; 71335-1054; 16436-0056; 63629-3405; 42043-210; 68788-7208; 71335-1466; 65862-215; 29300-132; 42043-211; 65862-214; 65862-197; 0054-0085; 71335-1387; 43063-912; 29300-131; 71335-0236; 57237-239; 51846-1026; 64330-054; 53296-0056; 57237-240; 45865-541
Synonyms zaleplon | 3'-(3-cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)-N-ethylacetanilide | N-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide | L 846 | L-846 | Zelepion | Starnoc | SKP-1041 | CL 284,846 | CL-284846 | CL284,846 | CL 284846 | Sonata
Chemical Information
Molecular Formula C17H15N5O
CAS Registry Number 151319-34-5
SMILES CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperacusis17.04.03.003; 04.02.02.001--Not Available
Hyperaesthesia17.02.06.004--Not Available
Hyperbilirubinaemia14.11.01.010; 09.01.01.003; 01.06.04.003--Not Available
Hypercholesterolaemia14.08.01.001--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hyperkinesia17.01.02.008--Not Available
Hyperreflexia17.02.01.002--Not Available
Hypertension24.08.02.001--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hyperuricaemia14.09.01.003--
Hyperventilation19.01.02.004; 22.02.01.006--Not Available
Hypoaesthesia17.02.06.023--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypokinesia17.01.02.009--Not Available
Hyporeflexia17.02.01.003--
Hypotension24.06.03.002--
Hypothyroidism05.02.03.001; 14.11.01.012--
Hypotonia17.05.02.002; 15.05.04.008--Not Available
Immune system disorder10.02.01.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intestinal obstruction07.13.01.002--Not Available
Irritability08.01.03.011; 19.04.02.013--
Joint stiffness15.01.02.003--Not Available
Joint swelling15.01.02.004--Not Available
Ketosis14.01.01.001--Not Available
Labyrinthitis11.01.05.002; 04.04.03.001--Not Available
Lacrimation increased06.08.02.004--
Lactase deficiency14.02.02.003; 07.17.01.006--Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 10 Pages